Clinical Trials
84 trialsHIFU-UPS
University of California, San Francisco
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
INVOKE
Epkin
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Memorial Sloan Kettering Cancer Center
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
PIPER
Institut Bergonié
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
M.D. Anderson Cancer Center
REGOSTA
Centre Leon Berard
PROSARC-1
Oslo University Hospital
PROSARC-2
Oslo University Hospital
POTENTIATE
Boundless Bio, Inc.
PEMBROCABOSARC
Institut Bergonié
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
BioAtla, Inc.
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Memorial Sloan Kettering Cancer Center
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
ANNOUNCE
Eli Lilly and Company
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
M.D. Anderson Cancer Center
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Eastern Cooperative Oncology Group
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
DUET-3
Xencor, Inc.
ENVASARC
Tracon Pharmaceuticals Inc.
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Fred Hutchinson Cancer Center
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
St. Jude Children's Research Hospital
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
PROPANE
Herlev and Gentofte Hospital
STRASS
European Organisation for Research and Treatment of Cancer - EORTC
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
VORTEX
Sheffield Teaching Hospitals NHS Foundation Trust
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
ADCVCTAST
N.N. Petrov National Medical Research Center of Oncology